Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引:29
|
作者
Kuppen, Malou C. P. [1 ]
Westgeest, Hans M. [2 ]
van der Doelen, Maarten J. [3 ]
van den Eertwegh, Alphonsus J. M. [4 ]
Coenen, Jules L. L. M. [5 ]
Aben, Katja K. H. [6 ,7 ]
van den Bergh, Alphons C. M. [8 ]
Bergman, Andries M. [9 ]
van den Bosch, Joan [10 ]
Celik, Filiz [11 ]
Hendriks, Mathijs P. [12 ]
Lavalaye, Jules [13 ]
van der Meer, Saskia [14 ]
Polee, Marco B. [15 ]
Somford, Diederik M. [16 ]
van Oort, Inge M. [17 ]
Uyl-de Groot, Carin A. [1 ]
Gerritsen, Winald R. [3 ]
机构
[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands
[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands
[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands
[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands
[5] Isala, Dept Oncol, Zwolle, Netherlands
[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands
[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands
[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands
[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands
[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands
[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands
[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands
[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands
[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands
[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands
[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands
[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands
关键词
metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;
D O I
10.2217/fon-2020-0039
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.
引用
收藏
页码:1371 / 1384
页数:14
相关论文
共 50 条
  • [21] Impact of treatment delay in Radium-223 Dichloride therapy of metastatic castration-resistant prostate cancer patients
    Fosbol, M. O.
    Holm, S.
    Petersen, P. M.
    Daugaard, G.
    Mortensen, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S214 - S214
  • [22] Use of Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer
    Parker, Chris
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (11) : 723 - 725
  • [23] Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer
    Unda-Urzaiz, M.
    Sousa-Campo, R.
    Rodriguez-Antolin, A.
    Silva-Marins, C.
    Juarez-Soto, A.
    Minana-Lopez, B.
    Figueiredo-de Castro, A.
    Cozar-Olmos, J. M.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (04): : 227 - 237
  • [24] Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
    Cha, Tai-Lung
    Wu, Tony Tong-Lin
    Vogelzang, Nicholas John
    Huang, Chao-Yuan
    Huang, Shu-Pin
    Lin, Chia-Chi
    Ou, Yen-Chuan
    Pang, See-Tong
    Shen, Daniel Heung-Yuan
    Wu, Wen-Jeng
    Chang, Wayne Yen-Hwa
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2017, 116 (11) : 825 - 836
  • [25] The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
    Heinrich, Daniel
    Bektic, Jasmin
    Bergman, Andries M.
    Caffo, Orazio
    Cathomas, Richard
    Chi, Kim N.
    Daugaard, Gedske
    Keizman, Daniel
    Kindblom, Jon
    Kramer, Gero
    Olmos, David
    Omlin, Aurelius
    Sridhar, Srikala S.
    Tucci, Marcello
    van Oort, Inge
    Nilsson, Sten
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E223 - E231
  • [26] Radium-223 treatment in Metastatic Prostate Cancer: Prognostic Factors: Real-world Outcome
    Pearson, R.
    Jiang, X.
    Atkinson, S.
    Cumming, S.
    Burns, A.
    Frew, J.
    McMenemin, R.
    Pedley, I.
    Azzabi, A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S855 - S855
  • [27] The National Radium-223 Dichloride Audit group: Data from patients in UK oncology centers with metastatic castration-resistant prostate cancer treated with radium-223 dichloride.
    Randhawa, Manreet
    Jones, Robert J.
    Stratton, Irene
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] The National Radium-223 Dichloride Audit Group: Data from patients in United Kingdom oncology centers with metastatic castration-resistant prostate cancer treated with radium-223 dichloride
    Randhawa, Manreet
    Stratton, Irene
    Jones, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [29] Radium-223 dichloride in patients with castration-refractory prostate cancer
    Winter, B. M.
    von Rundstedt, F. -C.
    Grimm, M. -O.
    [J]. UROLOGE, 2017, 56 (11): : 1435 - 1439
  • [30] Clinical outcomes and treatment patterns in REASSURE : planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
    Higano, Celestia S.
    George, Daniel J.
    Shore, Neal D.
    Sartor, Oliver
    Miller, Kurt
    Conti, Peter S.
    Sternberg, Cora N.
    Saad, Fred
    Sade, Juan Pablo
    Bellmunt, Joaquim
    Smith, Matthew R.
    Chandrawansa, Kumari
    Sandstroem, Per
    Verholen, Frank
    Tombal, Bertrand
    [J]. ECLINICALMEDICINE, 2023, 60